Clinical and Translational Research
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1775-1790
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1775
Metabolic disorders and hepatitis: Insights from a Mendelian randomization study
Ling-Bo Liang, Xiang-Ping Liu, Ting-Rui Mao, Qiao-Li Su
Ling-Bo Liang, Ting-Rui Mao, Qiao-Li Su, General Practice Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Xiang-Ping Liu, Department of Primary Health Care, The Fourth People’s Hospital of Dazhu County, Dazhou 635100, Sichuan Province, China
Author contributions: Su QL and Liang LB and Mao TR designed and performed the experiments; Liang LB and Liu XP provided support for data analysis and writing the manuscript; Su QL provided the supervision, resources, discussion, design and peer review process; all the authors have seen and approved the manuscript.
Conflict-of-interest statement: Prof. Su has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiao-Li Su, MM, Professor, General Practice Ward, General Practice Medical Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, Chengdu 610041, Sichuan Province, China. 18980601358@163.com
Received: March 12, 2024
Revised: April 30, 2024
Accepted: May 17, 2024
Published online: June 27, 2024
Processing time: 110 Days and 2.4 Hours
Abstract
BACKGROUND

Hepatitis is a systemic disease that often results in various comorbidities. Meta-bolic disorders, the most common comorbidities in clinical practice, were selected for this study.

AIM

To investigate the causal relationship between comorbidities and hepatitis trea-tment outcomes.

METHODS

A total of 23583378 single nucleotide polymorphisms from 1248743 cases and related summaries of genome-wide association studies were obtained from online public databases. A two-sample Mendelian randomization (MR) was performed to investigate causality between exposure [type 2 diabetes mellitus (T2D), hyperlipidemia, and hypertension] and outcome (chronic hepatitis B or C in-fections).

RESULTS

The data supported the causal relationship between comorbidities and hepatitis infections, which will affect the severity of hepatitis progression and will also provide a reference for clinical researchers. All three exposures showed a link with progression of both hepatitis B (T2D, P = 0.851; hyperlipidemia, P = 0.596; and hypertension, P = 0.346) and hepatitis C (T2D, P = 0.298; hyperlipidemia, P = 0.141; and hypertension, P = 0.035).

CONCLUSION

The results of MR support a possible causal relationship between different ex-posures (T2D, hyperlipidemia, and hypertension) and chronic hepatitis progression; however, the potential mechanisms still need to be elucidated.

Keywords: Hepatitis; Comorbidity; Type 2 diabetes mellitus; Hyperlipidemia; Hypertension

Core Tip: In our study, the randomization model was well defined for the exposures [type 2 diabetes mellitus (T2D), hyperlipidemia, and hypertension] and outcomes (chronic hepatitis B and chronic hepatitis C) by two-sample Mendelian randomization (MR) analysis, and they showed capabilities for interaction with chronic hepatitis infection. The results of our MR support a possible causal relationship between different exposures (T2D, hyperlipidemia, and hypertension) and chronic hepatitis progression.